The blood borne infectious disease hepatitis C was initially recognized in the mid-20th century. It was termed as non-A non-B hepatitis in the 1970's while scientists worked to find and map out its unique structure. It was isolated and identified in the 1980's and treated initially with interferon alfa in 1986. Since the first mono-therapy of interferon alfa, there have been increasingly more effective therapies and more knowledge created for and about this virus. The objective of this paper is to discuss recent changes to the standard of care for Hepatitis C genotype 1 based on evidence from two newly released drugs: beceprevir and telaprevir.